OSI

ATTENTION NASDAQ: BIVI INVESTORS: Contact Berger Montague About a BioVie Inc. Class Action Lawsuit

Retrieved on: 
星期六, 二月 3, 2024
COVID-19, Lead, OSI, GCP, Clinical trial, Patient, Good clinical practice, FDA, Food, Court, Pharmaceutical industry

PHILADELPHIA, Feb. 03, 2024 (GLOBE NEWSWIRE) -- Berger Montague advises investors that a securities fraud class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) on behalf of purchasers of BioVie’s securities between August 5, 2021 and November 29, 2023, inclusive (the “Class Period”).

Key Points: 
  • PHILADELPHIA, Feb. 03, 2024 (GLOBE NEWSWIRE) -- Berger Montague advises investors that a securities fraud class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) on behalf of purchasers of BioVie’s securities between August 5, 2021 and November 29, 2023, inclusive (the “Class Period”).
  • Investor Deadline: Investors who purchased or acquired BioVie securities during the Class Period may, no later than March 19, 2024, seek to be appointed as a lead plaintiff representative of the class.
  • During the Class Period, BioVie conducted a Phase 3 clinical trial of NE3107, a drug being developed for the treatment of Alzheimer’s Disease.
  • Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against BioVie Inc. - BIVI

Retrieved on: 
星期六, 二月 3, 2024
Pomerantz, Macrocephaly, Ext, OSI, GCP, Science, News, Patient, Good clinical practice, Lung compliance, Scientific misconduct, Prior, Complaint, LLP, Court, Action Replay, Pharmaceutical industry

NEW YORK, Feb. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI).

Key Points: 
  • NEW YORK, Feb. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • The class action concerns whether BioVie and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mercury Systems, Onsemi, BioNTech, and BioVie and Encourages Investors to Contact the Firm

Retrieved on: 
星期六, 二月 3, 2024
Pfizer–BioNTech COVID-19 vaccine, Mercury Systems, Onsemi, EPS, Silicon carbide, COVID-19, Pfizer, Growth, CFO, GAAP, OSI, GCP, Clinical trial, News, BNTX, Patient, Good clinical practice, Mercury, Tesla, Inc., P.C, Complaint, FDA, POC, EV, BioNTech, Food, LTSA, Silicon, Risk, Acquisition, MRCY, Defendant, Sale, Accreditation, Small business, Glass house, Pharmaceutical industry

Mercury Systems is a technology company that produces component modules and subsystems for the aerospace and defense industries.

Key Points: 
  • Mercury Systems is a technology company that produces component modules and subsystems for the aerospace and defense industries.
  • On this news, the price of Mercury Systems common stock fell more than 17%, the complaint alleges.
  • The Mercury Systems class action lawsuit alleges that on this news, the price of Mercury Systems common stock fell nearly 10%.
  • For more information on the BioVie class action go to: https://bespc.com/cases/BIVI

BIOVIE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options

Retrieved on: 
星期五, 二月 2, 2024
COVID-19, Alzheimer's disease, Advertising, OSI, GCP, Clinical trial, Patient, Good clinical practice, FDA, Food, Risk, Defendant, Woman, LLP, Court, Pharmaceutical industry

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) and reminds investors of the March 19, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $25,000 investing in BioVie stock or options between August 5, 2021 and November 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • Upon trial completion, the Company found significant deviation from protocol and Good Clinical Practice (GCP) violations at 15 sites.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding BioVie’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

BioVie (BIVI) Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman

Retrieved on: 
星期四, 二月 1, 2024
Macrocephaly, Hagens Berman, COVID-19, SAN, OSI, GCP, Person, Science, News, Patient, Good clinical practice, Lung compliance, Scientific misconduct, Risk, Pharmaceutical industry

SAN FRANCISCO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now .
  • The litigation focuses on the propriety of BioVie’s disclosures concerning its adherence to Good Clinical Practice (“GCP”) and protocols related to its Phase 3 clinical trial of NE3107, a potential Alzheimer’s disease drug.
  • ]” This news drove the price of BioVie shares down $1.25, or almost 30% lower, on Nov. 9, 2023.
  • “We’re focused on investors’ losses and are investigating whether BioVie may have intentionally concealed GCP and protocol violations,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Osino Announces Receipt of Interim Order and Closing of Second and Final Tranche of Bridge Private Placement

Retrieved on: 
星期三, 一月 31, 2024
DPM, Supreme court, Offering, OSI, Special, Circular, Telephone, Namibian Stock Exchange, Prospectus, NSX, Interim order, TSX Venture Exchange, Arrangement, OSN, Engineering, Financial adviser

Pursuant to the Interim Order, the Special Meeting is scheduled to be held virtually by live webcast on March 1, 2024 at 8:30 a.m. (Vancouver time).

Key Points: 
  • Pursuant to the Interim Order, the Special Meeting is scheduled to be held virtually by live webcast on March 1, 2024 at 8:30 a.m. (Vancouver time).
  • Osino is also pleased to announce that it has completed the second and final tranche of its previously announced non-brokered private placement (the "Offering") of common shares of the Company (the "Osino Shares") to DPM.
  • The total number of Osino Shares issued pursuant to the Offering, including the initial tranche, was 8,849,557 Osino Shares for aggregate gross proceeds to the Company of C$9,999,999.41.
  • The Osino Shares were offered by way of private placement pursuant to applicable exemptions from prospectus requirements in British Columbia and Ontario.

OpenLogic by Perforce Releases 2024 State of Open Source Report In Collaboration with the Open Source Initiative and the Eclipse Foundation

Retrieved on: 
星期四, 二月 1, 2024
Eclipse, Growth, Open Source Initiative, Marketing, Perforce, OSI, Eclipse Foundation, Organization, AngularJS, CentOS, EOL, Interest, Software, OSS, Online shopping

MINNEAPOLIS, Feb. 1, 2024 /PRNewswire/ -- Perforce Software, a provider of solutions to enterprise teams requiring productivity, visibility, and scale along the development lifecycle, today unveiled the results of their annual open source survey — the 2024 State of Open Source Report. This year, OpenLogic by Perforce collaborated with the Eclipse Foundation in addition to the Open Source Initiative (OSI) to conduct the survey and produce the report.

Key Points: 
  • This year, OpenLogic by Perforce collaborated with the Eclipse Foundation in addition to the Open Source Initiative (OSI) to conduct the survey and produce the report.
  • The 2024 State of Open Source Report sheds light on the factors driving open source software (OSS) adoption, the most in-demand open source technologies, and the difficulties that teams using OSS most frequently encounter.
  • "One of the goals of this report is to assist organizations with open source strategy and governance, including IT security policy-making," said Javier Perez, Chief Open Source Evangelist at Perforce Software.
  • The 2024 State of Open Source Report also covers support and planning for end-of-life (EOL) or soon-to-be EOL software.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mercury Systems, Onsemi, BioNTech, and BioVie and Encourages Investors to Contact the Firm

Retrieved on: 
星期二, 一月 30, 2024
MRCY, Silicon, Onsemi, Patient, Good clinical practice, OSI, Mercury, CFO, Risk, GCP, Mercury Systems, P.C, Complaint, Accreditation, Growth, BioNTech, Pfizer, BNTX, GAAP, Sale, Acquisition, EPS, Food, COVID-19, LTSA, EV, FDA, Silicon carbide, Small business, POC, Clinical trial, Glass house, News, Defendant, Tesla, Inc., Pfizer–BioNTech COVID-19 vaccine, Pharmaceutical industry

Mercury Systems is a technology company that produces component modules and subsystems for the aerospace and defense industries.

Key Points: 
  • Mercury Systems is a technology company that produces component modules and subsystems for the aerospace and defense industries.
  • On this news, the price of Mercury Systems common stock fell more than 17%, the complaint alleges.
  • The Mercury Systems class action lawsuit alleges that on this news, the price of Mercury Systems common stock fell nearly 10%.
  • For more information on the BioVie class action go to: https://bespc.com/cases/BIVI

Investors Sue BioVie (BIVI) Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman

Retrieved on: 
星期一, 一月 29, 2024
Patient, Good clinical practice, Science, OSI, SAN, GCP, Lung compliance, Risk, Macrocephaly, Hagens Berman, Person, COVID-19, News, Scientific misconduct, Pharmaceutical industry

SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now .
  • The litigation focuses on the propriety of BioVie’s disclosures concerning its adherence to Good Clinical Practice (“GCP”) and protocols related to its Phase 3 clinical trial of NE3107, a potential Alzheimer’s disease drug.
  • ]” This news drove the price of BioVie shares down $1.25, or almost 30% lower, on Nov. 9, 2023.
  • “We’re focused on investors’ losses and are investigating whether BioVie may have intentionally concealed GCP and protocol violations,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against BioVie Inc. - BIVI

Retrieved on: 
星期五, 一月 26, 2024
Pomerantz, Patient, Good clinical practice, Science, OSI, LLP, GCP, Ext, Lung compliance, Complaint, Court, Macrocephaly, Action Replay, News, Scientific misconduct, Pharmaceutical industry

NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI).

Key Points: 
  • NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • The class action concerns whether BioVie and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.